You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ezetimibe, Simvastatin Drug Combination

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hypercholesterolemia Trial (ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium, Comparator: Placebo (unspecified))

Completed
Has Results
  • Hypercholesterolemia
  • ezetimibe (+) simvastatin
  • +2 more
  • (no location specified)
Feb 7, 2022

Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II Trial (ezetimibe (plus simvastatin), (plus simvastatin))

Completed
  • Atherosclerosis
  • +2 more
  • ezetimibe (plus simvastatin)
  • placebo (plus simvastatin)
  • (no location specified)
Feb 7, 2022

Cardiovascular Disorder, Diabetes Trial (ezetimibe (+) simvastatin, simvastatin 40 mg or atorvastatin 20 mg, Rosuvastatin)

Completed
Has Results
  • Cardiovascular Disorder
  • Diabetes Mellitus
  • ezetimibe (+) simvastatin
  • +3 more
  • (no location specified)
Feb 7, 2022

Healthy Lactating Women Trial in Las Vegas (Bempedoic Acid 180 MG Oral Tablet, Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral

Recruiting
  • Healthy Lactating Women
  • Bempedoic Acid 180 MG Oral Tablet
  • Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet
  • Las Vegas, Nevada
    PPD Development, Las Vegas Research Unit
Aug 27, 2023

Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation Trial in Seoul

Not yet recruiting
  • Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
  • ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
  • high-intensity statin monotherapy (atoravastatin 40mg)
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Mar 21, 2023

Hypercholesterolemia Trial (MK0653A, ezetimibe (+) simvastatin, Comparator: Rosuvastatin)

Completed
  • Hypercholesterolemia
  • MK0653A, ezetimibe (+) simvastatin
  • Comparator: Rosuvastatin
  • (no location specified)
Feb 3, 2022

Coronary Artery Disease, Dyslipidemias Trial in Yongin (a high dose of statin/ezetimib)

Recruiting
  • Coronary Artery Disease
  • Dyslipidemias
  • a high dose of statin/ezetimib
  • Yongin, Gyeonggi-do, Korea, Republic of
    Yongin Severance Hospital
Jun 14, 2023

Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease Trial (MK0653A , ezetimibe (+) simvastatin, Comparator:

Completed
  • Hypercholesterolemia
  • +2 more
  • MK0653A , ezetimibe (+) simvastatin
  • +2 more
  • (no location specified)
Feb 3, 2022

Hypercholesterolemia, Coronary Disease Trial (Ezetimibe/Simvastatin 10/20 mg, simvastatin 40 mg)

Completed
Has Results
  • Hypercholesterolemia
  • Coronary Disease
  • Ezetimibe/Simvastatin 10/20 mg
  • simvastatin 40 mg
  • (no location specified)
Feb 7, 2022

Metabolic Syndrome Trial in Houston (Simvastatin, Vytorin, Placebo)

Completed
  • Metabolic Syndrome
  • Houston, Texas
    Baylor College of Medicine
Jul 21, 2022

Vytorin Tablet Among Filipino Patients

Completed
Has Results
  • Hypercholesterolemia
  • Vytorin (R) (Ezetimibe + Simvastatin)
  • (no location specified)
Feb 7, 2022

Hypercholesterolemia, Hyperlipidemia Trial (Vytorin + Niaspan, Vytorin, Niaspan)

Completed
  • Hypercholesterolemia
  • Hyperlipidemia
  • Vytorin + Niaspan
  • +2 more
  • (no location specified)
Feb 7, 2022

Cardiovascular Disorder Trial (Ezetimibe, simvastatin)

Completed
  • Cardiovascular Disorder
  • (no location specified)
Feb 7, 2022

A 52-week Post-marketing, Observational Study to Confirm Safety

Completed
  • Hypercholesterolemia
  • +2 more
  • Ezetimibe
  • Ezetimibe + other lipid-lowering medication(s)
  • (no location specified)
Feb 7, 2022

A 12-week Post-marketing, Observational Study to Confirm Safety

Completed
  • Hypercholesterolemia
  • +2 more
  • Ezetimibe
  • Ezetimibe + other lipid-lowering medication(s)
  • (no location specified)
Feb 7, 2022

Dyslipidemia Trial (Ezetimibe/simvastatin, Other Statin)

Withdrawn
  • Dyslipidemia
  • (no location specified)
Feb 7, 2022

Bempedoic Acid Pregnancy Surveillance Program

Recruiting
  • Pregnancy
  • Hyperlipidemias
  • Bempedoic Acid
  • Bempedoic Acid / Ezetimibe
  • Morrisville, North Carolina
    Evidera, PPD business unit
Oct 21, 2021

Cholesterol Trial (ezetimibe, Comparator: Placebo (unspecified), simvastatin)

Completed
  • Cholesterol
  • (no location specified)
Feb 7, 2022

Diabetes, Type 2 Trial in Hong Kong (Simvastatin 10mg, Ezetimibe 10mg)

Enrolling by invitation
  • Diabetes Mellitus, Type 2
  • Simvastatin 10mg
  • Ezetimibe 10mg
  • Hong Kong, Hong Kong
    Diabetes Centre, 2/F, Block L, Department of Medicine, Queen Mar
Nov 21, 2022

Describe Key Factors Leading to Physician's Decision to Treat

Completed
  • Hypercholesterolemia
  • Mixed Dyslipidemia
  • Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab
  • No study drug
  • Arnsberg, Germany
  • +62 more
Nov 30, 2022

Type 1 Diabetes, Dyslipidemia Trial in Aurora (Simvastatin, Ezetimibe/Simvastatin)

Completed
Has Results
  • Type 1 Diabetes Mellitus
  • Dyslipidemia
  • Aurora, Colorado
    Barbara Davis Center for Childhood Diabetes
Oct 19, 2020

Hypercholesterolaemia, Atherosclerosis Trial (Ezetimibe + Simvastatin, Simvastatin)

Completed
  • Hypercholesterolaemia
  • Atherosclerosis
  • (no location specified)
Feb 7, 2022

Hypercholesterolemia Trial (Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin), Double Statin (simvastatin,

Completed
Has Results
  • Hypercholesterolemia
  • Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)
  • Double Statin (simvastatin, atorvastatin, or pravastatin)
  • (no location specified)
Feb 7, 2022

Coronary Disease Trial (MK0653, ezetimibe / Duration of Treatment: 27 Weeks, MK0733, simvastatin / Duration of Treatment: 27

Completed
  • Coronary Disease
  • MK0653, ezetimibe / Duration of Treatment: 27 Weeks
  • +2 more
  • (no location specified)
Feb 7, 2022

Diabetes, Type 2 Trial (MK0653, ezetimibe / Duration of Treatment: 30 Weeks, Comparator : ezetimibe (+) simvastatin / Duration

Completed
  • Diabetes Mellitus, Type 2
  • MK0653, ezetimibe / Duration of Treatment: 30 Weeks
  • Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks
  • (no location specified)
Feb 7, 2022